摘要
目的 采用重组人IFN-γ治疗20例慢性乙型肝炎肝纤维化患者，通过治疗前后肝组织活检，观察其组织病理学的变化。 方法 20例慢性乙型肝炎患者，肝纤维化分期在2～4期。采用重组人IFN-γ肌注，开始3月每日一次，其后6月隔日1次，每次100万U，疗程为9个月。组织病理学观察包括HE染色和天狼红染色。使用肝纤维化半定量计分方案评价治疗前后肝纤维化程度变化。另测治疗前后血清肝纤维化指标，包括血清透明质酸、Ⅳ型胶原、Ⅲ型前胶原、层粘蛋白等四项指标。 结果 20例患者经IFN-γ治疗9月后，其肝纤维化计分由治疗前的11.24±5.34下降为治疗后的8.67±4.16（P＜0.01）；治疗后的炎症计分由治疗前的12.78±5.19下降为治疗后的6.57±2.95（P＜0.01）。 结论 IFN-γ能较好改善慢性乙型肝炎肝纤维化患者的肝纤维化程度，证明其有良好的抗肝纤维化治疗效果。
Objective To observe histological changes of hepatic fibrosis patients with chronic hepatitis B after recombinant human interferon-γ treatment. Methods Twenty hepatic fibrosis patients with chronic hepatitis B received rhIFN-γ treatment at the dose of 1 MU intramuscularly daily for the first three months and every other day for the next six months. Liver biopsy was performed at the start of the therapy and the end of 9-month follow-up period respectively in all patients. All liver biopsy specimens were stained with hematoxylin-eosin and picro-sirius red. Modified Scheuer and Chevallier semi-quantitative scoring system was used to assess the results. In the meantime, serum hepatic fibrosis indices and serum biochemical examination were detected. Results After 9 moths of treatment, the mean fibrosis score decreased from 11.24±5.34 to 8.67±4.16 (P<0.01), whereas the mean inflammation score decreased from 12.78±5.19 to 6.57±2.95 (P<0.01). Conclusions rhIFN-γ showes a beneficial effect on hepatic fibrosis patients with chronic hepatitis B. [
出处
《中华肝脏病杂志》
CAS
CSCD
2001年第5期273-275,共3页
Chinese Journal of Hepatology
